|20.72||+0.2100||+1.02%||Vol 233.89K||1Y Perf 28.35%|
|Dec 1st, 2023 16:00 DELAYED|
|- -||- -%|
|Target Price||14.35||Analyst Rating||Hold 2.67|
|Potential %||-30.74||Finscreener Ranking||★+ 43.19|
|Insiders Trans % 3/6/12 mo.||-/-/-||Value Ranking||★★★ 51.30|
|Insiders Value % 3/6/12 mo.||-/-/-||Growth Ranking||★ 38.77|
|Insiders Shares Cnt. % 3/6/12 mo.||-/-/-||Income Ranking||★★★+ 48.03|
|Price Range Ratio 52W %||43.72||Earnings Rating||Sell|
|Market Cap||12.16B||Earnings Date||2nd Nov 2023|
Today's Price Range
5 Year PE Ratio Range
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||-|
|Estimated EPS Next Report||0.37|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||293.18K|
|Avg. Monthly Volume||573.41K|
|Avg. Quarterly Volume||565.62K|
Fresenius Medical Care AG (NYSE: FMS) stock closed at 20.51 per share at the end of the most recent trading day (a 0.2% change compared to the prior day closing price) with a volume of 249.05K shares and market capitalization of 12.16B. Is a component of indices and it is traded on NYSE exchange. The company belongs in the Healthcare Providers & Services industry, Healthcare sector and employs 125364 people. Fresenius Medical Care AG CEO is Rice Powell.
The one-year performance of Fresenius Medical Care AG stock is 28.35%, while year-to-date (YTD) performance is 25.52%. FMS stock has a five-year performance of -49.68%. Its 52-week range is between 15.285 and 27.715, which gives FMS stock a 52-week price range ratio of 43.72%
Fresenius Medical Care AG currently has a PE ratio of 12.20, a price-to-book (PB) ratio of 0.60, a price-to-sale (PS) ratio of 0.65, a price to cashflow ratio of 4.10, a PEG ratio of 0.93, a ROA of 2.00%, a ROC of 3.60% and a ROE of 5.32%. The company’s profit margin is 4.87%, its EBITDA margin is 18.20%, and its revenue ttm is $15.46 Billion , which makes it $26.34 revenue per share.
Of the last four earnings reports from Fresenius Medical Care AG, there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $0.37 for the next earnings report. Fresenius Medical Care AG’s next earnings report date is -.
The consensus rating of Wall Street analysts for Fresenius Medical Care AG is Hold (2.67), with a target price of $14.35, which is -30.74% compared to the current price. The earnings rating for Fresenius Medical Care AG stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Fresenius Medical Care AG has a dividend yield of 4.15% with a dividend per share of $0.71 and a payout ratio of 31.00%.
Fresenius Medical Care AG has a Neutral technical analysis rating based on Technical Indicators (ADX : 10.49, ATR14 : 0.41, CCI20 : 92.62, Chaikin Money Flow : 0.24, MACD : 0.57, Money Flow Index : 82.31, ROC : 19.31, RSI : 71.76, STOCH (14,3) : 96.18, STOCH RSI : 1.00, UO : 65.48, Williams %R : -3.82), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Fresenius Medical Care AG in the last 12-months were:
Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
General partner of Finscreener is SLOVAKODATA, a.s.
This could take some time, please wait.